Artelo Biosciences (ARTL) Cash & Equivalents (2014 - 2025)

Artelo Biosciences (ARTL) has reported Cash & Equivalents for 12 consecutive years, with $600000.0 the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents fell 74.34% year-over-year to $600000.0; the TTM figure through Dec 2025 stood at $600000.0 (down 74.34% YoY), while the FY2025 annual figure was $600000.0, down 74.34% from the prior year.
• Cash & Equivalents declined to $600000.0 in Q4 2025 per ARTL's latest filing, from $1.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $14.0 million in Q4 2021 and bottomed at $600000.0 in Q4 2025.
• Historically, Cash & Equivalents has averaged $5.5 million across 5 years, with a median of $5.0 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 685.79% — and 2024, when it slumped 84.6%.
• Artelo Biosciences' Cash & Equivalents stood at $14.0 million in 2021, then plunged by 50.96% to $6.9 million in 2022, then plunged by 59.13% to $2.8 million in 2023, then declined by 16.94% to $2.3 million in 2024, then tumbled by 74.34% to $600000.0 in 2025.
• Business Quant data shows ARTL's Cash & Equivalents at $600000.0 in Q4 2025, $1.7 million in Q3 2025, and $2.1 million in Q2 2025.